Healthcare / BiotechnologyShenzhen
$26.45
-0.73 (-2.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-58.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
63.0x
↑EV/EBITDA
16.6x
↑ROE
3.4%
↑Gross Margin
16.7%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.7%
FCF CAGR
—
FCF margin
-18.5%
FCF / Net income
-1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $432.7M · net income $64.3M · FCF $-79.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $432.7M | $432.7M | $429.5M | $489.3M | $568.2M |
| Net Income | $64.3M | $64.3M | $16.4M | $112.2M | $177.3M |
| EBITDA | $122.9M | $122.9M | $67.3M | $185.3M | $254.6M |
| EPS | 0.71 | 0.71 | 0.18 | 1.22 | 2.06 |
| Gross Margin | 16.7% | 16.7% | 19.6% | 38.4% | 45.2% |
| Operating Margin | -1.9% | -1.9% | -0.3% | 19.7% | 30.2% |
| Net Margin | 14.9% | 14.9% | 3.8% | 22.9% | 31.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 10.36 | 10.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-79.9M | $-79.9M | $-58.2M | $53.1M | $101.1M |
| Returns | |||||
| ROE | 3.4% | 3.4% | 0.9% | 5.8% | 9.4% |
| Valuation | |||||
| P/E | 62.98 | 62.98 | 124.22 | 25.78 | 19.81 |
| EV/EBITDA | 16.55 | 16.55 | 26.95 | 13.73 | 12.78 |
| P/B | 1.28 | 1.28 | 1.08 | 1.49 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | -12.2% | -13.9% | — |
| EPS Growth | 294.4% | 294.4% | -85.2% | -40.8% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
49.0%
EPS terminal req.
$2.35
Spread vs growth
245.5%
5Y implied EPS CAGR
31.9%
EPS terminal req.
$2.84
Spread vs growth
262.5%
10Y implied EPS CAGR
20.5%
EPS terminal req.
$4.57
Spread vs growth
274.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.9%
Start / end P/E
182.9x → 37.3x
EPS bridge
0.18 → 0.71
Residual
-234.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.